Zai Lab (NASDAQ:ZLAB) Posts Quarterly Earnings Results, Misses Expectations By $0.19 EPS

Zai Lab (NASDAQ:ZLAB) released its earnings results on Thursday. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19), Zacks reports. The firm had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. Zai Lab updated its FY 2025 guidance to EPS.

Zai Lab Stock Performance

Zai Lab stock opened at $34.38 on Friday. The stock’s 50 day moving average price is $27.35 and its two-hundred day moving average price is $25.63. The stock has a market capitalization of $3.76 billion, a price-to-earnings ratio of -12.41 and a beta of 1.02. Zai Lab has a 52-week low of $13.48 and a 52-week high of $36.60.

Analyst Ratings Changes

Separately, Cantor Fitzgerald raised shares of Zai Lab to a “strong-buy” rating in a research note on Wednesday, February 5th.

Insider Activity at Zai Lab

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of Zai Lab stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total value of $199,281.24. Following the completion of the sale, the insider now directly owns 33,834 shares of the company’s stock, valued at approximately $889,157.52. The trade was a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 13.88% of the stock is owned by corporate insiders.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.